To Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®)
Launched by CGBIO INC. · Nov 3, 2016
Trial Information
Current as of September 28, 2025
Unknown status
Keywords
ClinConnect Summary
to evaluate the efficacy and safety of Mediclore®, as an antiadhesive barrier
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • the patients with submucosal myomas, endometrial polyps, intra-uterine adhesion, uterine septa, dysfunctional uterine bleeding
- • Written informed consent
- • Patients without clinically significant lab
- Exclusion Criteria:
- • having enrolled another clinical trials within 1 month
- • Immunosuppression or autoimmune disease
- • Anticoagulant, general steroids within a week from surgery
- • Incompatible medications
- • Serious diseases (heart failure, renal failure, liver failure, uncontrolled hypertension, diabetes mellitus, coagulation deficiencies)
About Cgbio Inc.
cgbio Inc. is a clinical-stage biotechnology company dedicated to advancing innovative therapies in the field of regenerative medicine. With a strong focus on harnessing the potential of cellular technologies, cgbio aims to develop transformative treatments that address unmet medical needs across various therapeutic areas. The company is committed to rigorous scientific research and clinical trials, leveraging its expertise to bring safe and effective solutions to patients. cgbio's mission is to improve quality of life through cutting-edge medical advancements, while maintaining a strong emphasis on safety, efficacy, and ethical practices in all aspects of its operations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul City, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials